T. Blum (Berlin, Germany), M. Evison (Manchester, United Kingdom)
LSC - 2017 - The serum levels of alpha-1 antitrypsin are strongly associated with its local production by NSCLC tumor cells A. Szpechcinski (Warszawa, Poland)
| |
Detection of non-small cell lung cancer by an electronic nose. S. Kort (Enschede, Netherlands)
| |
Non-invasive lung cancer diagnosis by detection of GATA6 and NKX2-1 isoforms in exhaled breath condensate G. Barreto (Bad Nauheim, Germany)
| |
Metabolomic fingerprinting of serum samples based on direct infusion mass spectrometry for lung cancer diagnosis B. Urizar Catalan (Huelva, Spain)
| |
Single Slide Assessment: the future of molecular testing in lung cancer? B. Diggins (Truro, United Kingdom)
| |
Performance of Super ARMS to Detect EGFR Mutation Status in Plasma Cell-free DNA in Advanced Non-Small Cell Lung Cancer Patients Y. Li (wenzhou, China)
| |
Next generation sequencing in lung adenocarcinoma of smokers with and without chronic obstructive pulmonary disease (COPD) F. Lunardi (Padova, PD, Italy)
| |
Effects of tumor stroma and inflammation on survival of stage I-IIp lung cancer L. Millares Costas (Badalona (Barcelona), Spain)
| |
The significance of AEG-1 expression in NSCLL: correlation with prognostic markers. E. Chaini (Corfu, Greece)
| |
Polymorphisms in mitotic checkpoint-related genes can influence survival outcomes of early-stage non-small cell lung cancer S. Yoo (Daegu, Republic of Korea)
| |
Association of the Monocyte Chemoattractant Protein 1 and Chemokine Receptor 2 Genetic Polymorphisms with Non-small Cell Lung Cancer in Taiwan C. Shih (Taichung, Taiwan)
| |
The value of AXL expression in squamous cell carcinoma of the lung: relationship with clinicopathological parameters. E. Chaini (Corfu, Greece)
| |
Predictive factors and prognostic significance of T790M mutation in patients with EGFR-mutant NSCLC J. Hwang (Seoul, Republic of Korea)
| |
T790M-mutation in EGFR progressive non-small cell lung cancer, role of re-biopsy and ctDNA analysis M. Jacob (PORTO, Portugal)
| |
Characteristics of common and uncommon epidermal growth factor receptros gene mutations in patients with non small cell lung cancer I. Merkyte (Kaunas, Lithuania)
| |
Survival analysis of advanced NSCLC patients harboring EGFR mutations with zoledronate or denosumab M. Miwa (Tokyo, Japan)
| |
Comparing different initial doses of afatinib used as first-line treatment for patients with stage IV lung adenocarcinoma Y. Tsai (Kaohsiung, Taiwan)
| |